Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04134923 · ClinicalTrials.gov registry record
Imaging Biomarkers in Preclinical and Symptomatic AD
A clinical trial of Alzheimer Disease, sponsored by Tammie L. S. Benzinger, MD, PhD.
- Recruiting
- Registry status
- 375
- Enrollment target
- 1
- Study location
NCT04134923 is a study of Alzheimer Disease that is actively recruiting participants, run by Tammie L. S. Benzinger, MD, PhD. The registered enrollment target is 375 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04134923, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Tammie L. S. Benzinger, MD, PhD.
- RECRUITING
- Registry status
- 375 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).
Conditions Studied
Interventions
- DRUG [11C] Pittsburgh Compound-B (PIB)
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2029-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04134923
The ClinicalTrials.gov registry entry for NCT04134923 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (86% lower). The listed sponsor is Tammie L. S. Benzinger, MD, PhD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which [11C] Pittsburgh Compound-B (PIB) is the first listed.
NCT04134923 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04134923 about?
NCT04134923 is a clinical study titled "Imaging Biomarkers in Preclinical and Symptomatic AD". The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of a...
What is the current status of trial NCT04134923?
This trial is currently recruiting. The enrollment target is 375 participants. The study started on 2021-06-08. Estimated completion is 2029-10.
What conditions does trial NCT04134923 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT04134923?
The interventions under investigation include: [11C] Pittsburgh Compound-B (PIB) (DRUG).
Who is sponsoring clinical trial NCT04134923?
This trial is sponsored by Tammie L. S. Benzinger, MD, PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04134923 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.